ABIVAX Société Anonyme (ABVX)
NASDAQ: ABVX · Real-Time Price · USD
132.56
-0.70 (-0.53%)
At close: Jul 1, 2026, 4:00 PM EDT
140.80
+8.24 (6.22%)
Pre-market: Jul 2, 2026, 4:04 AM EDT
ABIVAX Société Anonyme Revenue
ABIVAX Société Anonyme had revenue of 1.34M EUR in the quarter ending March 31, 2026, with 35.21% growth. This brings the company's revenue in the last twelve months to 4.92M, down -59.82% year-over-year. In the year 2025, ABIVAX Société Anonyme had annual revenue of 4.57M, down -63.22%.
Revenue (ttm)
4.92M EUR
Revenue Growth
-59.82%
P/S Ratio
1,880.08
Revenue / Employee
61,500 EUR
Employees
80
Market Cap
10.67B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.57M | -7.86M | -63.22% |
| Dec 31, 2024 | 12.43M | 7.85M | 171.67% |
| Dec 31, 2023 | 4.57M | 69.00K | 1.53% |
| Dec 31, 2022 | 4.51M | 302.00K | 7.19% |
| Dec 31, 2021 | 4.20M | 4.19M | 29,921.43% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioMarin Pharmaceutical | 3.24B |
| Bio-Techne | 1.21B |
| Madrigal Pharmaceuticals | 1.13B |
| Corcept Therapeutics | 769.10M |
| Arrowhead Pharmaceuticals | 622.01M |
| Krystal Biotech | 417.30M |
| ImmunityBio | 140.98M |
| Cytokinetics | 105.82M |
ABVX News
- 2 hours ago - Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M) - GlobeNewsWire
- 9 hours ago - Abivax nears $11 billion valuation after fundraising eases M&A pressure - Reuters
- 19 hours ago - Correction: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares - GlobeNewsWire
- 19 hours ago - Abivax announces trading resumption of its ordinary shares on Euronext Paris - GlobeNewsWire
- 19 hours ago - Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares - GlobeNewsWire
- 1 day ago - Abivax announces temporary trading halt of its ordinary shares on Euronext Paris - GlobeNewsWire
- 1 day ago - Abivax announces $600M ADS offering - TheFly
- 1 day ago - Abivax Announces Launch of Public Offering of American Depositary Shares - GlobeNewsWire